CoChat

ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling

Open access
Schmidt, Stefanie, Schumacher, Neele, Schwarz, Jeanette, Tangermann, Simone, Kenner, Lukas, Schlederer, Michaela, Sibilia, Maria, Linder, Markus, Altendorf-Hofmann, Annelore, Knösel, Thomas, Gruber, Elisabeth S., Oberhuber, Georg, Bolik, Julia, Rehman, Ateequr, Sinha, Anupam, Lokau, Juliane, Arnold, Philipp, Cabron, Anne-Sophie, Zunke, Friederike, Becker-Pauly, Christoph, Preaudet, Adele, Nguyen, Paul, Huynh, Jennifer, Afshar-Sterle, Shoukat, Chand, Ashwini L., Westermann, Jürgen, Dempsey, Peter J., Garbers, Christoph, Schmidt-Arras, Dirk, Rosenstiel, Philip, Putoczki, Tracy, Ernst, Matthias, Rose-John, Stefan · 2018 · Journal of Experimental Medicine
Cited by 80

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Colorectal cancer is treated with antibodies blocking epidermal growth factor receptor (EGF-R), but therapeutic success is limited. EGF-R is stimulated by soluble ligands, which are derived from transmembrane precursors by ADAM17-mediated proteolytic cleavage. In mouse intestinal cancer models in the absence of ADAM17, tumorigenesis was almost completely inhibited, and the few remaining tumors were of low-grade dysplasia. RNA sequencing analysis demonstrated down-regulation of STAT3 and Wnt pathway components. Because EGF-R on myeloid cells, but not on intestinal epithelial cells, is required for intestinal cancer and because IL-6 is induced via EGF-R stimulation, we analyzed the role of IL-6 signaling. Tumor formation was equally impaired in IL-6−/− mice and sgp130Fc transgenic mice, in which only trans-signaling via soluble IL-6R is abrogated. ADAM17 is needed for EGF-R–mediated induction of IL-6 synthesis, which via IL-6 trans-signaling induces β-catenin–dependent tumorigenesis. Our data reveal the possibility of a novel strategy for treatment of colorectal cancer that could circumvent intrinsic and acquired resistance to EGF-R blockade.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20171696

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 80

Metadata

Authors
Schmidt, S., Schumacher, N., Schwarz, J., Tangermann, S., Kenner, L., Schlederer, M., Sibilia, M., Linder, M., Altendorf-Hofmann, A., Knösel, T., Gruber, E. S., Oberhuber, G., Bolik, J., Rehman, A., Sinha, A., Lokau, J., Arnold, P., Cabron, A.-S., Zunke, F., Becker-Pauly, C., Preaudet, A., Nguyen, P., Huynh, J., Afshar-Sterle, S., Chand, A. L., Westermann, J., Dempsey, P. J., Garbers, C., Schmidt-Arras, D., Rosenstiel, P., Putoczki, T., Ernst, M., & Rose-John, S.
Venue
Journal of Experimental Medicine
Published
2018-02-22
Volume
215
Issue
4
Pages
1205-1225
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2793384878
Cited by
80
References
18
FWCI
4.21
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling. https://app.cochat.ai/papers/10.1084/jem.20171696
The paper
Schmidt, S., Schumacher, N., Schwarz, J., Tangermann, S., Kenner, L., Schlederer, M., Sibilia, M., Linder, M., Altendorf-Hofmann, A., Knösel, T., Gruber, E. S., Oberhuber, G., Bolik, J., Rehman, A., Sinha, A., Lokau, J., Arnold, P., Cabron, A.-S., Zunke, F., . . . Rose-John, S. (2018). ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20171696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.